NCT03815825: An ongoing trial by Ionis Pharmaceuticals, Inc.
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03815825 |
|---|---|
| Title | A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 4, 2019 |
| Completion date | April 18, 2024 |
| Required reporting date | April 18, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |